US Patent Issued to TargED Biopharmaceuticals on May 26 for "Fusion protein for targeted thrombolysis for treatment of microvascular thrombosis" (Dutch Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,636,351, issued on May 26, was assigned to TargED Biopharmaceuticals B.V. (Utrecht, Netherlands).

"Fusion protein for targeted thrombolysis for treatment of microvascular thrombosis" was invented by Coen Maas (Utrecht, Netherlands) and Steven De Maat (Utrecht, Netherlands).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with s...